ADA Scientific Sessions 2025 Abstract

ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

By Jinzi Jason Wu, Chuyan Wu

Experiments in animalsInterventions

The paper

Jinzi Jason Wu, Chuyan Wu

Hong Kong

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 847-P

doi.org/10.2337/db25-847-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
JCI Insight6 Oct 2026
Antibody reduced fat while preserving lean mass in mice
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety